|
|
T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel
|
|
|
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
|
|
|
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
|
|
|
T2 Biosystems Announces Pricing of $12 Million Public Offering
|
|
|
T2 Biosystems Announces Proposed Public Offering
|
|
|
T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
|
|
|
T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize
|
|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
|
